Blog Archive

Αλέξανδρος Γ. Σφακιανάκης

Loading...

Monday, November 23, 2020

Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC

Cancer shared this article with you from Inoreader
Condition:   Hepatocellular Carcinoma Intervention:   Drug: Anti-angiogenic agents plus anti-PD-1/PD-L1 antibodies Sponsor:   Shanghai Zhongshan Hospital Recruiting (Source: ClinicalTrials.gov)
View on the web
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)